

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Spesolimab for treating generalised pustular psoriasis flares ID3963

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Boehringer Ingelheim Ltd (spesolimab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Changing Faces Gene People Genetic Alliance UK Psoriasis and Psoriatic Arthritis Alliance Psoriasis Association Psoriasis Help Organisation South Asian Health Foundation Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> Association of Genetic Nurses & Counsellors British Association of Dermatologists British Dermatological Nursing Group British Geriatrics Society British Society for Cutaneous Allergy British Society for Genetic Medicine Primary Care Dermatology Society Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine St John's Institute of Dermatology UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> Department of Health and Social Care NHS England 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> AbbVie (adalimumab, risankizumab) Accord Healthcare (methotrexate) Advanz Pharma (methotrexate) Almirall (dimethyl fumarate, tildrakizumab) Amgen (adalimumab, apremilast) Aspire Pharma (dimethyl fumarate) Biogen Idec (adalimumab, dimethyl fumarate, etanercept, infliximab) Bristol Myers Squibb (deucravacitinib) B&S Colorama (ciclosporin) Celltrion Healthcare UK (adalimumab, infliximab) Celix Pharma (dimethyl fumarate) Dexcel-Pharma (ciclosporin) Eli Lilly and Company (ixekizumab)

Provisional stakeholder list for the evaluation of spesolimab for treating generalised pustular psoriasis flares ID3963

Issue date: June 2024 © National Institute for Health and Care Excellence 2024. All rights reserved.

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Fresenius Kabi (adalimumab) • Genus Pharmaceuticals (acitretin, dimethyl fumarate) • Hospira UK (methotrexate) • Johnson & Johnson Innovative Medicine (guselkumab, ustekinumab) • Leo Pharma (brodalumab) • Medac GmbH (methotrexate) • Merck Sharp & Dohme (infliximab) • Morningside Healthcare (acitretin, ciclosporin, methotrexate) • Mylan (ciclosporin, dimethyl fumarate) • Nordic Pharma (methotrexate) • Novartis Pharmaceuticals UK (ciclosporin, secukinumab) • Orion Pharma (UK) (methotrexate) • Pfizer (etanercept, infliximab, methotrexate) • Rosemont Pharmaceuticals (methotrexate) • Sandoz (adalimumab, etanercept, infliximab, methotrexate) • Santen UK (ciclosporin) • Teva UK (acitretin, ciclosporin, methotrexate) • Therakind Limited (methotrexate) • UCB Pharma (bimekizumab, certolizumab pegol) • Viartis (ciclosporin) • Wockhardt (dimethyl fumarate) • Zentiva (dimethyl fumarate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Skin Foundation • Centre of Evidence-based Dermatology, University of Nottingham • Cochrane Skin Group • Dermatrust • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a Confidentiality Agreement & Undertakings form is signed at appraisal stage.